Literature DB >> 22805857

K-ras mutation is strongly associated with perineural invasion and represents an independent prognostic factor of intrahepatic cholangiocarcinoma after hepatectomy.

Tse-Ching Chen1, Yi-Yin Jan, Ta-Sen Yeh.   

Abstract

BACKGROUND: Unsatisfying long-term survival of intrahepatic cholangiocarcinoma (ICC) triggers the clinicians searching for molecular markers, such as K-ras mutation, to tailor management strategy. Additionally, emergence of tyrosine kinase inhibitors (TKIs) brings new hope to palliate advanced ICC; whether the efficacy of TKIs is influenced by k-ras mutation is largely unknown. This study was designed to determine the prevalence of k-ras mutation and its clinical significance in ICC, as well as to pave the reference for future application of TKIs.
METHODS: A total of 86 patients with ICC who underwent hepatectomy were retrospectively recruited. K-ras mutation was determined by using laser capture microdissection and direct sequencing method. Association among clinicopathological variables and K-ras mutation was analyzed. Prognostic factors of ICC after hepatectomy also were determined.
RESULTS: Nineteen (22%) patients exhibited K-ras mutations. Seventeen had their K-ras mutations occurring at codon 12, and the remaining two occurring at codon 13 and codon 61 in one each. Perineural invasion was exclusively the variable associated with K-ras mutation (odds ratio, 6.9) using logistic regression analysis. Multivariate analysis demonstrated that resection margin, T-status, nodal metastasis, and K-ras mutation were independent prognostic factors. The median survival of ICC patients with K-ras mutation was 5.7 months compared with 19.0 months in those without K-ras mutation (P = 0.002).
CONCLUSIONS: The prevalence of K-ras mutations in a considerably large cohort of ICC was 22%. K-ras mutation is strongly associated with perineural invasion phenotypically. K-ras mutation is an independent prognostic factor of ICC after hepatectomy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22805857     DOI: 10.1245/s10434-012-2224-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  20 in total

1.  Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis.

Authors:  Sarah B Fisher; Sameer H Patel; David A Kooby; Sharon Weber; Mark Bloomston; Clifford Cho; Ioannis Hatzaras; Carl Schmidt; Emily Winslow; Charles A Staley; Shishir K Maithel
Journal:  HPB (Oxford)       Date:  2012-05-22       Impact factor: 3.647

2.  KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.

Authors:  Nancy E Kemeny; Joanne F Chou; Marinela Capanu; Alexandra N Gewirtz; Andrea Cercek; T Peter Kingham; William R Jarnagin; Yuman C Fong; Ronald P DeMatteo; Peter J Allen; Jinru Shia; Celina Ang; Efsevia Vakiani; Michael I D'Angelica
Journal:  Cancer       Date:  2014-08-25       Impact factor: 6.860

Review 3.  Current biologics for treatment of biliary tract cancers.

Authors:  Diana Y Zhao; Kian-Huat Lim
Journal:  J Gastrointest Oncol       Date:  2017-06

4.  Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas.

Authors:  Masayuki Akita; Kohei Fujikura; Tetsuo Ajiki; Takumi Fukumoto; Kyoko Otani; Takeshi Azuma; Tomoo Itoh; Yonson Ku; Yoh Zen
Journal:  Mod Pathol       Date:  2017-03-24       Impact factor: 7.842

Review 5.  New Horizons for Precision Medicine in Biliary Tract Cancers.

Authors:  Juan W Valle; Angela Lamarca; Lipika Goyal; Jorge Barriuso; Andrew X Zhu
Journal:  Cancer Discov       Date:  2017-08-17       Impact factor: 39.397

Review 6.  Review to better understand the macroscopic subtypes and histogenesis of intrahepatic cholangiocarcinoma.

Authors:  Yuichi Sanada; Yujo Kawashita; Satomi Okada; Takashi Azuma; Shigetoshi Matsuo
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

Review 7.  Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.

Authors:  Tolutope Oyasiji; Jianliang Zhang; Boris Kuvshinoff; Renuka Iyer; Steven N Hochwald
Journal:  Oncologist       Date:  2015-05-29

8.  A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.

Authors:  Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Hepat Oncol       Date:  2014-01-01

Review 9.  Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.

Authors:  D Sia; V Tovar; A Moeini; J M Llovet
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

10.  WTAP regulates migration and invasion of cholangiocarcinoma cells.

Authors:  Hong-Jae Jo; Hye-Eun Shim; Myoung-Eun Han; Hyun-Jung Kim; Ki-Sun Kim; Sungmin Baek; Kyung-Un Choi; Gi-Yeong Hur; Sae-Ock Oh
Journal:  J Gastroenterol       Date:  2013-01-25       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.